Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Donald Trump to surrender to New York prosecutors on Tuesday
    • ‘Dare to fight’: Xi Jinping unveils China’s new world order
    • Vladimir Putin’s new doctrine calls US ‘main source’ of threat to Russian security
    • Pro-Trump protesters fail to show up in New York
    • The cases facing Donald Trump
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Banks in turmoil
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • UK is global equity markets ‘backwater’, Nick Train warns
      • Mis-steps that brought Virgin Orbit crashing back to earth
      • EY bosses present united front after dispute over stalled break-up plan
      • Colm Kelleher: Irish financial crisis veteran orchestrating Credit Suisse takeover
      • New John Lewis boss tells employees business must change ‘at pace’
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      Most Read
      • Prepare for a multipolar currency world
      • UK is global equity markets ‘backwater’, Nick Train warns
      • Live news updates from March 31: Nasdaq posts biggest quarterly gain since 2020, Eurozone inflation slows
      • Flood of cash into US money market funds could add to banking strains
      • Nasdaq records best quarter since 2020 after volatile start to year
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
      Most Read
      • We are living through a trillion-dollar rebalancing
      • Why are Americans dying so young?
      • Prepare for a multipolar currency world
      • The wheels of justice turn for a former US president
      • Law versus man: Trump’s courtroom drama begins
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • Boomerang chief executives provide comfort in times of crisis
      • Matthew Desmond: ‘America does so much more to subsidise affluence than alleviate poverty’
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • Serhiy Prytula: ‘The defence minister said: “Try to buy a satellite.” I thought he was joking’
      • I used AI to bet on horse-racing. Here’s what happened
      • Homebuyers chase their European dreams despite economic outlook
      • Essay: Is being a perfectionist really a bad thing?
      • Chinese artists test censorship’s new red line
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    BioNTech

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Monday, 27 March, 2023
      BioNTech forecasts slump in sales as demand for Covid jab wanes

      Expected fall highlights challenges for pharmaceutical companies that experienced pandemic windfall

    • Tuesday, 10 January, 2023
      BioNTech buys UK AI start-up InstaDeep in £562mn deal

      Covid vaccine maker looks to use machine learning to help discover new treatments

    • Friday, 6 January, 2023
      Medical science
      UK signs deal with BioNTech for cutting-edge cancer trials

      Covid-19 vaccine maker hails ‘huge’ investment aimed at recruiting 10,000 participants with NHS

    • Monday, 2 January, 2023
      LexDrugs research
      Moderna/BioNTech: cancer vaccines will show mRNA not a one-trick pony Premium content

      Success in battle against Covid does not ensure success against tumours, but should narrow the odds

    • Monday, 7 November, 2022
      Profits drop at BioNTech as Covid vaccine demand wanes

      Fall from €3.2bn in the third quarter of 2021 to €1.8bn

    • Sunday, 16 October, 2022
      Covid-19 vaccines
      Vaccine makers face revenue slump as demand falls for Covid jabs

      Pharmaceutical companies hunt for new revenue streams as coronavirus becomes endemic

    • Thursday, 13 October, 2022
      InterviewCovid-19 vaccines
      Beijing’s failure to import mRNA Covid jabs ‘mind-boggling’, says BeiGene executive

      Chinese biotech’s research chief calls decision ‘unfortunate’ as zero-Covid policy strangles economy

    • Wednesday, 28 September, 2022
      Behind the Money podcast18 min listen
      Who will pay for the next Covid vaccines?

      Experts are concerned that the US isn’t doing enough to support the development of the next wave of vaccines and treatments that the world needs to fight the Covid-19 pandemic

    • Wednesday, 31 August, 2022
      Covid-19 vaccines
      US approves Omicron vaccines from Moderna and BioNTech/Pfizer

      FDA clears jabs despite lack of human trials in effort to curb winter wave of Covid infections

    • Friday, 26 August, 2022
      Covid-19 vaccines
      Moderna accuses BioNTech/Pfizer of copying mRNA technology

      US biotech claims rival Covid vaccine makers infringed patents underpinning jabs developed to combat the pandemic

    • Monday, 22 August, 2022
      Covid-19 vaccines
      Pfizer and BioNTech ask US regulator to authorise variant-specific jab

      Vaccine targeting BA.4/BA.5 could become first shot to win green light without human trials

    • Monday, 8 August, 2022
      Covid-19 vaccines
      BioNTech and Pfizer to begin vaccine clinical trial for new Covid variants

      German biotech aims for ‘prolonged and broad protection’ as sales and earnings miss expectations

    • Tuesday, 19 July, 2022
      LexCovid-19 vaccines
      Covid-19 vaccines: shape-shifting virus puts agile manufacturers at an advantage Premium content

      The latest strains have spread fast and governments are trying to catch up

    • Tuesday, 5 July, 2022
      CureVac GmbH
      CureVac sues BioNTech over mRNA patents

      Pharma group seeks compensation from Covid vaccine maker for alleged IP infringements

    • Saturday, 25 June, 2022
      Covid-19 vaccines
      BioNTech/Pfizer say Omicron-targeting boosters elicit strong immune response

      New vaccine candidates significantly outperform existing Covid jabs at targeting the most prevalent strain

    • Saturday, 18 June, 2022
      Covid-19 vaccines
      BioNTech chief calls for speedy ruling on Covid vaccines that target latest strains

      ‘Time is ticking’ as studies suggest original Omicron jabs may not offer strong protection against sub-variants

    • Wednesday, 15 June, 2022
      Covid-19 vaccines
      FDA advisory panel backs Covid-19 vaccines for children under 5

      US prepares to roll out jabs to last age group without access once regulatory approval is received

    • Tuesday, 14 June, 2022
      The Big Read
      BioNTech’s second act: can it transform the fight against cancer?

      The German company is ploughing Covid vaccine profits into oncology but its technology is still largely unproven

    • Wednesday, 8 June, 2022
      Lex
      BioNTech/pancreatic cancer: mRNA jabs may tame a savage disease Premium content

      German biotech’s promising early-stage results make it a sought-after partner

    • Monday, 9 May, 2022
      Covid-19 vaccines
      BioNTech beats forecasts on back of Covid vaccine demand

      German biotech maintains guidance but prepares for fall in sales because of jab oversupply

    • Tuesday, 5 April, 2022
      Pfizer Inc
      Chief executives of mRNA vaccine groups earned $100mn in pandemic pay

      Remuneration at the three big jab makers reflects surge in value of share options

    • Wednesday, 30 March, 2022
      BioNTech to return almost €2bn to shareholders after Covid vaccine success

      German biotech plans to boost R&D spending by 50% as quarterly earnings beat forecasts

    • Wednesday, 16 February, 2022
      Covid-19 vaccines
      Children aged 5 to 11 to be offered Covid vaccine in England

      Johnson government announces plan after similar moves in Scotland and Wales

    • Tuesday, 25 January, 2022
      Covid-19 vaccines
      BioNTech/Pfizer start clinical trial of Omicron vaccine

      First human study of variant-specific jab by big western drugmaker could prompt shift in manufacturing

    • Wednesday, 12 January, 2022
      Coronavirus pandemic
      BioNTech and AI start-up develop tool to predict high-risk coronavirus variants

      Hopes early warning system will give policymakers and vaccine producers more time to address health risks

    Previous page You are on page 1 Next page

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsSecondary Schools

    Tools

    PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition

    Top sections

    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Banks in turmoil
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports

    FT recommends

    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • FTfm
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Live Events
    • FT Forums
    • Board Director Programme
    • myFT
    • Portfolio
    • Today's Newspaper (ePaper)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In